Collecting blood samples from cancer patients for genetic analysis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to collect blood or cheek swab samples from individuals undergoing cancer treatment to analyze genetic differences that may influence treatment efficacy and side effects. Participants include those with various cancers, such as prostate, breast, lung, and ovarian cancers, as well as lymphoma. The study focuses on understanding how genetic variations affect drug metabolism and response to therapy, with the goal of improving treatment outcomes and minimizing adverse effects. A total of 1,100 patients will be enrolled to provide samples for genomic analysis.

Why it matters

Who can join: the full rules

* INCLUSION CRITERIA:
* Any individual currently enrolled in an NIH intramural research program clinical trials receiving treatment.
* Ability of participant or Legally Authorized Representative (LAR) to understand and be willing to sign the informed consent document.
* Age \>= 3 years old

EXCLUSION CRITERIA:

-N/A

Where it's running

• National Institutes of Health Clinical Center
  Bethesda, Maryland, United States Recruiting

Study contacts

• Principal investigator: William D Figg, Pharm.D. — National Cancer Institute (NCI)
• Study coordinator: Deneise C Francis, R.N.
• Email: deneise.francis@nih.gov
• Phone: (240) 858-3974

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Validation of a blood test for early cancer detection and monitoring

  This study is testing a blood test to see if it can help find different types of cancer early and monitor patients after treatment.

  Recruiting at 3 sites Adela, Inc · Duarte, California and 16 other locations · NCT05366881

• Collecting blood and leftover tumor tissue to test molecular residual disease (MRD) detection

  This project will test whether blood and leftover tumor tissue from adults with certain solid tumors can be used with Natera's MRD blood tests to find tiny amounts of cancer (ctDNA) after treatment.

  Recruiting Natera, Inc. · Austin, Texas · NCT07318051

• Virtual exercise program to preserve function and prevent disability during chemotherapy

  This trial tests whether supervised resistance sessions by video plus short home aerobic workouts help adults 18–64 maintain strength and stay active while receiving curative-intent chemotherapy.

  Recruiting at 29 sites Alliance for Clinical Trials in Oncology · Dublin, California and 29 other locations · NCT07059884

• IDOV-Immune for advanced solid tumors

  This trial will try a single IV infusion of an engineered oncolytic vaccinia virus called IDOV-Immune in adults with advanced solid tumors that no longer respond to standard treatments.

  Recruiting at 5 sites Phase 1 ViroMissile, Inc. · St Louis, Missouri and 4 other locations · NCT06910657

• Treatment for adult patients with solid tumors that have a specific p53 mutation

  This study is testing a new treatment for adults with advanced solid tumors that have a specific p53 mutation to see if it is safe and effective.

  Recruiting at 21 sites Phase 1 Clasp Therapeutics, Inc. · Scottsdale, Arizona and 20 other locations · NCT06778863

• Investigating QXL138AM for patients with advanced solid tumors and multiple myeloma

  This study is testing a new drug called QXL138AM to see if it can safely help people with advanced solid tumors and multiple myeloma.

  Recruiting at 11 sites Phase 1 Nammi Therapeutics Inc · Los Angeles, California and 10 other locations · NCT06582017

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.